Hematological Oncology

Published by: Wiley Blackwell  

People

  1. Horwitz
    Horwitz
  2. Palomba
    Palomba
  3. Moskowitz
    Moskowitz
  4. Zelenetz
    Zelenetz
  5. Yahalom
    Yahalom
  6. Kumar
    Kumar
  7. Noy
    Noy
  8. Hamlin
    Hamlin
  9. Salles
    Salles
  10. Imber
    Imber

Groups

  1. Center for Hematologic Malignancies (133)
  2. Department of Medicine (133)
  3. Hematologic Malignancies, Division of (133)
  4. Lymphoma (110)
  5. Survivorship Research (41)
  6. Population Sciences Research Program (38)
  7. Executive Committee, Center for Hematologic Malignancies (26)
  8. Epidemiology and Biostatistics (22)
  9. Bone Marrow Transplant (20)
  10. Radiation Oncology, Department of (20)
Search Within
  1. "Center for Hematologic Malignancies"
Formats
  1. Meeting Abstract (122)
  2. Journal Article (6)
  3. Review (3)
  4. Conference Paper (2)
Groups
  1. Center for Hematologic Malignancies (133)
  2. Department of Medicine (133)
  3. Hematologic Malignancies, Division of (133)
  4. Lymphoma (110)
  5. Survivorship Research (41)
  6. Population Sciences Research Program (38)

More Groups

People
  1. Steven Horwitz (38)
  2. Maria Palomba (30)
  3. Alison Moskowitz (23)
  4. Anas Younes (22)
  5. Matthew Matasar (22)
  6. Andrew Zelenetz (21)

More People

Years
  1. 2023 (34)
  2. 2022 (1)
  3. 2021 (22)
  4. 2020 (1)
  5. 2019 (43)
  6. 2018 (1)

More Years

Publishers
  1. Wiley Blackwell (133)

Results (133)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (LISO‐CEL) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia‐Sancho, A. M.; Reguera Ortega, J. L.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (LISO‐CEL) in R/R MCL: Primary analysis results from the MCL cohort of the single-arm, multicenter, seamless design transcend NHL 001 study
    Meeting Abstract

    Wang, M.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Daratumumab and EPOCH for HIV+/‐ plasmablastic lymphoma: A feasibility study of the AIDS Malignancy Consortium (AMC 105)
    Meeting Abstract

    Noy, A.; Barta, S. K.; Tan, C. R.; Kwon, D.; Baiocchi, R.; Rubinstein, P.; Ambinder, R.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A phase I study of split‐course bringing radiotherapy (SC‐BRT) prior to commercial CD19 CAR T‐cell therapies for patients with relapsed or refractory B‐cell lymphomas
    Meeting Abstract

    Imber, B. S.; Yahalom, J.; Palomba, M. L.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Phase 1 study of PRT1419 (MCL1 inhibitor) as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory myeloid or B‐cell malignancies
    Meeting Abstract

    Zuniga, R. R.; Nair, S.; Keiffer, G.; Ravandi‐Kashani, F.; Goldberg, A. D.; Traer, E.; Frenzel, L. P.; Röllig, C.; Savickas, G.; Sun, W.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • ZUMA‐24: A phase 2, open-label study of axicabtagene ciloleucel in patients with relapsed/refractory large B‐cell lymphoma given outpatient with corticosteroids
    Meeting Abstract

    Leslie, L.; Tees, M.; Flinn, I. W.; Rodriguez, T. E.; Baird, J. H.; Deol, A.; Mead, M.; Bachier, C.; Rapoport, A. P.; McClune, B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Drug‐resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradation
    Meeting Abstract

    Montoya, S.; Bourcie, J.; Sondhi, A.; Jahn, J.; Alencar, A.; Abdel-Wahab, O.; Taylor, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • MicroRNAs regulate novel signaling pathways targetable by PI3K, MEK, BCL6 and EZH2 inhibitors in ibrutinib resistance mantle cell lymphoma
    Meeting Abstract

    Kersy, O.; Salmon‐Divon, M.; Gomes da Silva, M.; Moita, F.; Cabecadas, J.; Trněný, M.; Basood, M.; Abdel-Wahab, O.; Klener, P.; Shpilberg, O.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Multicenter experience with radiotherapy for relapse after chimeric antigen receptor T cell therapy in non‐Hodgkin lymphoma
    Meeting Abstract

    Hubbeling, H.; Figura, N.; Ladbury, C.; Keit, E. R.; Chew, J.; Fregonese, B.; Silverman, E. A.; Hajj, C.; Shah, G.; Kambhampati, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CNS radiotherapy as bridging prior to CAR T‐cell therapy for hematologic malignancies
    Meeting Abstract

    Cederquist, G.; Hubbeling, H.; Tringale, K.; Shah, G.; Alarcon Tomas, A.; Shouval, R.; Hajj, C.; Fregonese, B.; Lee, J.; Dahi, P. B.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save

    • Hematological Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 02780232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 02780232 John Wiley & Sons
    Hematological Oncology 0278-0232 Unknown
    Hematological Oncology 0278-0232 John Wiley & Sons
    Hematological Oncology 0278-0232 Wiley Blackwell